1
/
of
1
Elabscience
SKU:PKSV030351
Recombinant SARS-CoV-2 Spike RBD(S494P)(His Tag)
Recombinant SARS-CoV-2 Spike RBD(S494P)(His Tag)
Regular price
$1,105.00 USD
Regular price
Sale price
$1,105.00 USD
Unit price
/
per
Shipping calculated at checkout.
Couldn't load pickup availability
Introducing the Recombinant SARS-CoV-2 Spike RBD(S494P)(His Tag), a cutting-edge product designed to facilitate advanced research and development in the field of virology. This meticulously engineered recombinant protein offers a highly purified and reliable solution for studying the Spike Receptor Binding Domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Crafted with utmost precision, the Recombinant SARS-CoV-2 Spike RBD(S494P)(His Tag) showcases an innovative S494P mutation, enabling enhanced stability and improved binding affinity. This strategic modification empowers researchers to delve deeper into the intricate mechanisms of viral entry and host cell interaction, thereby unraveling crucial insights into the pathogenesis of COVID-19.
With its His Tag, this recombinant protein ensures facile purification and efficient detection, streamlining experimental workflows and expediting data acquisition. Its exceptional purity, achieved through rigorous quality control measures, guarantees optimal performance and reproducibility, instilling confidence in experimental outcomes.
The Recombinant SARS-CoV-2 Spike RBD(S494P)(His Tag) is meticulously manufactured in state-of-the-art facilities, adhering to stringent industry standards. Each batch undergoes meticulous characterization, including SDS-PAGE analysis and mass spectrometry, to ensure batch-to-batch consistency and integrity.
This product is intended for research purposes only and is not suitable for diagnostic or therapeutic applications. It is supplied in lyophilized form, preserving its stability and extending its shelf life. Upon reconstitution, it exhibits exceptional solubility, facilitating seamless integration into a wide range of experimental protocols.
In summary, the Recombinant SARS-CoV-2 Spike RBD(S494P)(His Tag) represents a breakthrough tool for scientists and researchers dedicated to unraveling the mysteries of SARS-CoV-2. Its unparalleled quality, stability, and versatility make it an indispensable asset in the pursuit of understanding the viral dynamics and developing effective countermeasures against COVID-19.
Crafted with utmost precision, the Recombinant SARS-CoV-2 Spike RBD(S494P)(His Tag) showcases an innovative S494P mutation, enabling enhanced stability and improved binding affinity. This strategic modification empowers researchers to delve deeper into the intricate mechanisms of viral entry and host cell interaction, thereby unraveling crucial insights into the pathogenesis of COVID-19.
With its His Tag, this recombinant protein ensures facile purification and efficient detection, streamlining experimental workflows and expediting data acquisition. Its exceptional purity, achieved through rigorous quality control measures, guarantees optimal performance and reproducibility, instilling confidence in experimental outcomes.
The Recombinant SARS-CoV-2 Spike RBD(S494P)(His Tag) is meticulously manufactured in state-of-the-art facilities, adhering to stringent industry standards. Each batch undergoes meticulous characterization, including SDS-PAGE analysis and mass spectrometry, to ensure batch-to-batch consistency and integrity.
This product is intended for research purposes only and is not suitable for diagnostic or therapeutic applications. It is supplied in lyophilized form, preserving its stability and extending its shelf life. Upon reconstitution, it exhibits exceptional solubility, facilitating seamless integration into a wide range of experimental protocols.
In summary, the Recombinant SARS-CoV-2 Spike RBD(S494P)(His Tag) represents a breakthrough tool for scientists and researchers dedicated to unraveling the mysteries of SARS-CoV-2. Its unparalleled quality, stability, and versatility make it an indispensable asset in the pursuit of understanding the viral dynamics and developing effective countermeasures against COVID-19.
Share
